Unspecified 'tba' receptor target (TBA)

The term "Unspecified 'tba' receptor target" is a placeholder designation typically found in pharmacological databases and clinical trial registries. It most commonly refers to the undisclosed molecular target of a drug candidate developed by the Global Alliance for TB Drug Development, also known as the TB Alliance (abbreviated as TBA). Compounds in this pipeline, such as TBA-7371 or TBA-354, are often assigned a "TBA" prefix before their specific biological target is formally categorized in a database record. For instance, while TBA-7371 is now known to target the enzyme DprE1 (decaprenylphosphoryl-beta-D-ribose 2'-epimerase) in Mycobacterium tuberculosis, other experimental agents may be listed with an "unspecified" target during early-stage research. Additionally, "TBA" is sometimes used as a generic acronym for "To Be Announced" or "To Be Assigned" in data management systems when a target has not yet been identified or disclosed by the sponsor. Consequently, this entry does not represent a single, recognized biological receptor or protein but rather serves as an administrative label for missing or pending target information.

Other names

TB Alliance targetTo be announced targetUndisclosed TBA targetTo be assigned

Varies by specific compound; for example, TBA-7371 inhibits DprE1 (decaprenylphosphoryl-beta-D-ribose 2'-epimerase).